The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lopac-R-108     (3,4-dihydroxy-5-nitro- phenyl)-(2...

Synonyms: AC1MRNAO, R108_SIGMA, CHEMBL1256291, SureCN6036458, OR-1139, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Psychiatry related information on OR 1139

  • 2. QO IA (3-(3-hydroxy-4-methoxy-5-nitrobenzylidene)-2,4-pentanedione), QO IIR ([2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone), nitecapone and Ro-41-0960 (30 mg kg(-1), i.p.) were given to reserpinized rats 1 h before the administration of L-DOPA/carbidopa (LD/CD, 50:50 mg kg(-1), i.p.). Locomotor activity was assessed 1 h later [1].

High impact information on OR 1139


Associations of OR 1139 with other chemical compounds


Gene context of OR 1139

  • Distinct interindividual variations were observed in sensitivity toward COMT inhibition among the various tissue samples, as was shown by the range in IC(50) values for Ro 41-0960 (5-42 nM) [6].

Analytical, diagnostic and therapeutic context of OR 1139

  • Investigations of L-DOPA uptake in rat striatal cultures using HPLC revealed a significant reduction of extracellular L-DOPA concentrations by Ro 41-0960 [2].


  1. In vivo effects of new inhibitors of catechol-O-methyl transferase. Rivas, E., de Ceballos, M.L., Nieto, O., Fontenla, J.A. Br. J. Pharmacol. (1999) [Pubmed]
  2. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity. Blessing, H., Bareiss, M., Zettlmeisl, H., Schwarz, J., Storch, A. Neurochem. Int. (2003) [Pubmed]
  3. Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter. Percy, E., Kaye, D.M., Lambert, G.W., Gruskin, S., Esler, M.D., Du, X.J. Br. J. Pharmacol. (1999) [Pubmed]
  4. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. Törnwall, M., Tuomainen, P., Männistö, P.T. Archives internationales de pharmacodynamie et de thérapie. (1992) [Pubmed]
  5. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Miller, J.W., Shukitt-Hale, B., Villalobos-Molina, R., Nadeau, M.R., Selhub, J., Joseph, J.A. Clinical neuropharmacology. (1997) [Pubmed]
  6. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage. van Duursen, M.B., Sanderson, J.T., de Jong, P.C., Kraaij, M., van den Berg, M. Toxicol. Sci. (2004) [Pubmed]
WikiGenes - Universities